Zeba's Feed
Nov 6, 2015

Dr Reddy’s gets FDA warning on three drug plants

MUMBAI (Reuters) – Dr Reddy’s Laboratories Ltd, India’s second-largest drugmaker by sales, said on Friday it has received a “warning letter” from the U.S. Food and Drug Administration over what the regulator has deemed inadequate quality control procedures at three manufacturing plants in southern India.

The warning letter means Dr Reddy’s will not receive FDA approvals to sell drugs manufactured at the plants for now, a blow for business at a company which relies on the United States for a majority of its sales. The plants make a significant contribution to company sales, with one alone accounting for 10-12 percent, Dr Reddy’s said.

Nov 6, 2015

India’s Dr Reddy’s gets FDA warning on three drug plants

MUMBAI (Reuters) – Dr Reddy’s Laboratories Ltd, India’s second-largest drugmaker by sales, said on Friday it has received a “warning letter” from the U.S. Food and Drug Administration over what the regulator has deemed inadequate quality control procedures at three manufacturing plants in southern India.

The warning letter means Dr Reddy’s will not receive FDA approvals to sell drugs manufactured at the plants for now, a blow for business at a company which relies on the United States for a majority of its sales. The plants make a significant contribution to company sales, with one alone accounting for 10-12 percent, Dr Reddy’s said.

Oct 29, 2015

Dr Reddy’s plans bigger push on biosimilars in emerging markets

MUMBAI (Reuters) – Dr Reddy’s Laboratories Ltd plans to step up sales of biosimilars, or copies of complex biotech drugs, in emerging markets in the next few years, its chief operating officer said on Thursday.

Biosimilars are a lucrative category of medicines that is expected to generate billions of dollars in sales in the next few years, but Indian drugmakers are lagging their Western peers in launching biosimilars in developed markets.

Oct 29, 2015

India’s Dr Reddy’s plans bigger push on biosimilars in emerging markets

MUMBAI, Oct 29 (Reuters) – Indian drugmaker Dr Reddy’s
Laboratories Ltd plans to step up sales of
biosimilars, or copies of complex biotech drugs, in emerging
markets in the next few years, its chief operating officer said
on Thursday.

Biosimilars are a lucrative category of medicines that is
expected to generate billions of dollars in sales in the next
few years, but Indian drugmakers are lagging their Western peers
in launching biosimilars in developed markets.

Oct 21, 2015

Idea Cellular Q2 profit lags estimates as cheaper call rates hurt

MUMBAI, Oct 21 (Reuters) – Idea Cellular Ltd,
India’s third-biggest mobile operator, posted quarterly net
profit slightly below analysts’ expectations, hit by a drop in
call rates and intense competition on mobile data charges.

Call rates have become cheaper in the past few months,
hurting the entire mobile industry. But Idea lagged rival Bharti
Airtel in adding new customers to its network in July
and August.

Oct 16, 2015

India drug industry says U.S.-led trade deal will raise prices

NEW DELHI (Reuters) – Leaders of India’s $15 billion pharmaceuticals industry, a major supplier of affordable generics to the world, have joined public health activists in criticizing a new U.S.-led trade deal they say will delay the arrival of new cheap drugs.

The impact of the Trans-Pacific Partnership (TPP) struck last week between 12 nations, which include the United States but not India, is still being studied by Indian drug makers. But in initial comments, industry executives said provisions in the deal that shield new drug data from competitors would hurt their business in those nations.

Oct 14, 2015

India risks missing boat as biosimilars shake up drug industry

MUMBAI (Reuters) – India, which has dominated the generic drugs industry for decades, is falling behind in the race to make copies of complex biotech drugs, which are expected to generate tens of billions of dollars in sales in the coming years. While Indian firms have launched a few such products on the domestic market, where regulatory barriers are relatively low, they are being overtaken by European, American and South Korean firms in the race to supply lucrative Western markets. Just three Indian groups – Biocon Ltd (BION.NS: Quote, Profile, Research, Stock Buzz), Dr Reddy’s Laboratories Ltd (REDY.NS: Quote, Profile, Research, Stock Buzz) and Intas Pharamceuticals Ltd – are working with partners on so-called biosimilars aimed at the United States and Europe.

Biotech drugs, which require genetic engineering, account for a growing share of new drugs and the future sales of copycat products will also switch to this category of pharmaceuticals from simple small-molecule pills like aspirin. The global biosimilars market is predicted to have sales of $25 billion by 2020, according to a 2014 Thomson Reuters report. “Biosimilars is a big opportunity,” said Sujay Shetty, leader of the life sciences practice at PwC India. “But unlike generics, it is not yet an opportunity (for Indian companies) in the U.S.”

Oct 14, 2015

Drug retailers protest against e-pharmacies

NEW DELHI/MUMBAI (Reuters) – Drug retailers shut up shop for the day on Wednesday to protest against the country’s growing online pharmacy industry, and threatened to close indefinitely if the federal government did not shut down e-pharmacies.

The nationwide protest was widely supported, with as many as 850,000 chemists closing their doors, leaving patients waiting in long queues at any pharmacies that were open.

Oct 14, 2015

Indian drug retailers protest against e-pharmacies

NEW DELHI/MUMBAI, Oct 14 (Reuters) – Indian drug retailers
shut up shop for the day on Wednesday to protest against the
country’s growing online pharmacy industry, and threatened to
close indefinitely if the federal government did not shut down
e-pharmacies.

The nationwide protest was widely supported, with as many as
850,000 chemists closing their doors, leaving patients waiting
in long queues at any pharmacies that were open.

Oct 12, 2015

Rosier year-end seen for Indian pharma thanks to faster U.S. approvals

MUMBAI, Oct 12 (Reuters) – India’s pharmaceutical industry
is expected to see sales and profit growth accelerate in the
second half of the year, thanks to a pickup in the pace of U.S.
approvals for new drugs, offsetting any downturn in volatile
emerging markets.

Analysts say a jump in approvals by the U.S. Food and Drug
Administration (FDA) for companies such as Lupin Ltd,
Aurobindo Pharma Ltd and Glenmark Pharmaceuticals Ltd
will mean better sales in the United States, and
therefore a rosier end to the year through March 2016.

    • About Zeba

      "Zeba is responsible for covering India's thriving pharmaceuticals and healthcare industries from Mumbai. She earlier reported on U.S. biotechnology and healthcare companies from the Bangalore bureau. She holds a post-graduate degree in journalism from India, and is fluent in Hindi, Urdu and Marathi."
      Joined Reuters:
      2011
    • More from Zeba

    • Contact Zeba

    • Follow Zeba